Effect of Preoperative Alpha-Blocker in Ureteroscopy for Ureteral Stones: A Case-Control Study | ||
| Al- Anbar Medical Journal | ||
| Article 3, Volume 18, Issue 1, June 2022, Pages 10-14 PDF (373.25 K) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2021.174524 | ||
| Authors | ||
| Asaad I Othman* ; Nabeel M Al-Hamamy | ||
| Department of Surgery (Urology), Al-Jumhory Teaching hospital, Nineveh Health Directorate, Mosul, Nineveh, Iraq. | ||
| Abstract | ||
| Background: Urothethiasis is the most common urinary tract disease with a global prevalence rate of 2-20%. Alfa-blocker has a relaxation effect on the smooth muscles of the ureter making the removal of ureteric stone easier during the ureteroscopic procedure. Objectives: To evaluate the effect of preoperative α-adrenoreceptor antagonists therapy (tamsulosin) in the treatment of ureteral stone using a ureteroscope regarding operative time, access to the ureter, and the complication rate. Materials and Methods: A prospective case-control study was conducted at Al-Jamhory Teaching Hospital, Mosul, Iraq. During the period from June 2019 to August 2020. Subjectts with ureteral stones (7-15 mm) scheduled for ureteroscopic intervention were enrolled in the study. The patients were classified into two groups, the first group was received a pre-operative alpha-blocker (tamsulosin 0.4 mg capsule per day for 7 days), and the second group (Control) did not receive further medication. The operative time, uretric access, and intra- and postoperative complications were registered for both groups. Results: There was a matching between the two groups regarding the age, gender, and side, size, and location of the ureteric stones. There was a statistically significant difference between the two groups regarding the operative time (23.2 ± 4.569 minute in the treated group vs. 25.48 ± 4.904 minute in the control group) (P-value = 0.009). Besides, the ureteroscopic operation was easier (P-value = 0.031) in treated group (n = 51 easy case, 85%) than the control group (n=41, 68.33% easy case). The intraoperative and postoperative complications were mucosal injury, perforation, bleeding, pain, hematuria, and fever. The total number of complicated cases was 14 (23.33%) in the treated group and 25 (41.66%) in the control group, and there was a significant difference between the two groups (P-value = 0.032). Conclusion: The study revealed that the preoperative alpha-blocker tamsulosin was improved the outcome of ureteroscopy (shorter operative time, easier access to the ureter, and low complication rate). | ||
| Keywords | ||
| Ureteric stone; Ureteroscopy; Alfa-Blocker; Tamsulosin | ||
| References | ||
|
[1] A. Sokhal et al., “Do pre-operative alpha blockers facilitate ureteroscope insertion at the vesico-ureteric junction? An answer from a prostective case–controlled study,” Eur Med J, vol. 2, pp. 82–86, 2017.
[2] N. Rashahmadi, H. Sofimajidpour, A. Saedi, and G. Moradi, “The effect of tamsulosin on the quality and complications of ureteroscopy: A double blind clinical trial,” Med Sci, vol. 22, pp. 272–278, 2018.
[3] M. AHMED, A. L. I. M. GHONEIM, A. B. D. E.-H. M. EL-BAHNASY, and M. R. MAGED, “Study of the Effect of Tamsulosin HCl (an Alpha-1 Receptor Antagonist) as a Medical Expelling Agent on Subsequent Ureteroscopic Procedure for Treatment of Lower Ureteric Stones,” Med. J. Cairo Univ., vol. 86, no. September, pp. 2881–2889, 2018.
[4] S. Erturhan, Ö. Bayrak, H. Şen, A. E. Yılmaz, and İ. Seçkiner, “Can alpha blockers facilitate the placement of ureteral access sheaths in retrograde intrarenal surgery?,” Turkish J. Urol., vol. 45, no. 2, p. 108, 2019.
[5] E. Perez-Castro Ellendt, “Laureterorrenoscopia transuretral: un actual proceder urologico,” Arch. Esp. Urol., vol. 33, pp. 445–460, 1980.
[6] M. H. Ather, J. Paryani, A. Memon, and M. N. Sulaiman, “A 10‐year experience of managing ureteric calculi: changing trends towards endourological intervention—is there a role for open surgery?,” BJU Int., vol. 88, no. 3, pp. 173–177, 2001.
[7] R. Bhattar, V. Jain, V. Tomar, and S. S. Yadav, “Safety and efficacy of silodosin and tadalafil in ease of negotiation of large ureteroscope in the management of ureteral stone: A prosective randomized trial,” Turkish J. Urol., vol. 43, no. 4, p. 484, 2017.
[8] P. Geavlete, D. Georgescu, G. NiţĂ, V. Mirciulescu, and V. Cauni, “Complications of 2735 retrograde semirigid ureteroscopy procedures: a single-center experience,” J. Endourol., vol. 20, no. 3, pp. 179–185, 2006.
[9] A. Mohey, T. M. Gharib, H. Alazaby, M. Khalil, A. Abou-Taleb, and Y. A. Noureldin, “Efficacy of silodosin on the outcome of semi-rigid ureteroscopy for the management of large distal ureteric stones: blinded randomised trial,” Arab J. Urol., vol. 16, no. 4, pp. 422–428, 2018.
[10] J. Rajpathy, K. Aswathaman, M. Sinha, S. Subramani, G. Gopalakrishnan, and N. S. Kekre, “An in vitro study on human ureteric smooth muscle with the α1‐adrenoceptor subtype blocker, tamsulosin,” BJU Int., vol. 102, no. 11, pp. 1743–1745, 2008.
[11] Y. Itoh, Y. Kojima, T. Yasui, K. Tozawa, S. Sasaki, and K. Kohri, “Examination of alpha 1 adrenoceptor subtypes in the human ureter,” Int. J. Urol., vol. 14, no. 8, pp. 749–753, 2007.
[12] A. Ueno, T. Kawamura, A. Ogawa, and H. Takayasu, “Relation of spontaneous passage of ureteral calculi to size,” Urology, vol. 10, no. 6, pp. 544–546, 1977.
[13] M. S. Griwan, S. K. Singh, H. Paul, D. S. Pawar, and M. Verma, “The efficacy of tamsulosin in lower ureteral calculi,” Urol. Ann., vol. 2, no. 2, p. 63, 2010.
[14] A. S. Abdelaziz and A. M. Kidder, “Tamsulosin therapy improved the outcome of ureterorenoscopy for lower ureteral stones: A prospective, randomised, controlled, clinical trial,” African J. Urol., vol. 23, no. 2, pp. 148–153, 2017.
[15] V. Romero, H. Akpinar, and D. G. Assimos, “Kidney stones: a global picture of prevalence, incidence, and associated risk factors,” Rev. Urol., vol. 12, no. 2–3, p. e86, 2010.
[16] S. Neeli, “Effect of tamsulosin versus tamsulosin plus tadalafil on renal calculus clearance after shock wave lithotripsy: An open-labelled, randomised, prospective study,” Asian J. Urol., 2021.
[17] A. Bourdoumis, C. Tanabalan, A. Goyal, S. Kachrilas, N. Buchholz, and J. Masood, “The difficult ureter: stent and come back or balloon dilate and proceed with ureteroscopy? What does the evidence say?,” Urology, vol. 83, no. 1, pp. 1–3, 2014.
[18] O. M. Aboumarzouk, S. G. Kata, F. X. Keeley, and G. Nabi, “Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi,” Cochrane Database Syst. Rev., no. 12, 2011.
[19] F. Yencilek, K. Sarica, S. Erturhan, F. Yagci, and A. Erbagci, “Treatment of ureteral calculi with semirigid ureteroscopy: where should we stop?,” Urol. Int., vol. 84, no. 3, pp. 260–264, 2010.
[20] K. Bensalah, M. Pearle, and Y. Lotan, “Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones,” Eur. Urol., vol. 53, no. 2, pp. 411–419, 2008.
[21] M. Aydın, M. F. Kılınç, A. Yavuz, and G. Bayar, “Do alpha-1 antagonist medications affect the success of semi-rigid ureteroscopy? A prospective, randomised, single-blind, multicentric study,” Urolithiasis, vol. 46, no. 6, pp. 567–572, 2018.
[22] J. De La Rosette et al., “The clinical research office of the endourological society ureteroscopy global study: indications, complications, and outcomes in 11,885 patients,” J. Endourol., vol. 28, no. 2, pp. 131–139, 2014.
[23] H. M. Alaridy, K. M. A. Zwain, H. Q. Al-Mosawi, and N. R. Hadi, “Comparison of Silodosin, Tadalafil and Combinations Prior to Ureteroscopic Management of Ureteral Stones,” Syst. Rev. Pharm., vol. 11, no. 4, pp. 238–242, 2020. | ||
|
Statistics Article View: 236 PDF Download: 163 |
||